Zimmer Biomet Holdings Inc (ZBH)
Official siteHEALTHCARE • MEDICAL DEVICES • NYSE
Market Cap: $19.53B
Last updated: Nov 17, 2026 at 11:06 AM ET
Zimmer Biomet Holdings Inc (ZBH) Earnings: Report Dates and Results
Zimmer Biomet Holdings (ZBH) is expected to report earnings on Feb 8, 2027. In the quarter ended Sep 30, 2026, Zimmer Biomet Holdings reported EPS of $1.90, above the $1.89 estimate. It beat the EPS estimate in each of the last 8 quarters.
Earnings
Performance (10Y)
Upcoming Estimates
Next Report
ZBH has an expected report date of Feb 8, 2027. Analysts' consensus for the quarter ending Dec 31, 2026 is 3.7% above the $2.42 reported for the quarter ended Dec 31, 2025.
ZBH Earnings Call
The latest ZBH earnings call transcript on file is labeled 2026Q3.
Read the 2026Q3 transcriptEarnings History
Of the 40 quarters below that had an estimate, ZBH beat 35, missed 3 and matched 2. Revenue for the quarter ended Sep 30, 2026 was $2.06B, up 3.0% from $2.00B a year earlier.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported | Revenue |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | $1.90 | $1.89 | $1.86 - $1.91 | +0.53% | Beat | 0.0% | 24 | 12 up, 7 down | Nov 4, 2026 | $2.06B |
| Jun 30, 2026 | $2.07 | $2.01 | $1.98 - $2.05 | +2.99% | Beat | 0.0% | 24 | 0 up, 3 down | Aug 5, 2026 | $2.18B |
| Mar 31, 2026 | $2.09 | $1.86 | $1.84 - $1.93 | +12.37% | Beat | +15.5% | 24 | 1 up, 1 down | Apr 28, 2026 | $2.09B |
| Dec 31, 2025 | $2.42 | $2.40 | $2.35 - $2.45 | +0.83% | Beat | +4.8% | 24 | 1 up, 2 down | Feb 10, 2026 | $2.24B |
| Sep 30, 2025 | $1.90 | $1.88 | $1.72 - $1.95 | +1.06% | Beat | +9.2% | 24 | 2 up, 5 down | Nov 5, 2025 | $2.00B |
| Jun 30, 2025 | $2.07 | $1.98 | $1.79 - $2.07 | +4.55% | Beat | +3.0% | 23 | 0 up, 2 down | Aug 7, 2025 | $2.08B |
| Mar 31, 2025 | $1.81 | $1.77 | $1.71 - $1.92 | +2.26% | Beat | -6.7% | 25 | 3 up, 1 down | May 5, 2025 | $1.91B |
| Dec 31, 2024 | $2.31 | $2.29 | $2.24 - $2.34 | +0.87% | Beat | +5.0% | 27 | 0 up, 4 down | Feb 6, 2025 | $2.02B |
| Sep 30, 2024 | $1.74 | $1.74 | $1.63 - $1.96 | 0.00% | In line | +5.5% | 26 | 0 up, 1 down | Oct 30, 2024 | $1.82B |
| Jun 30, 2024 | $2.01 | $1.99 | $1.94 - $2.03 | +1.00% | Beat | +10.4% | 26 | 0 up, 0 down | Aug 7, 2024 | $1.94B |
| Mar 31, 2024 | $1.94 | $1.87 | $1.80 - $1.92 | +3.74% | Beat | +2.6% | 25 | 1 up, 2 down | May 2, 2024 | $1.89B |
| Dec 31, 2023 | $2.20 | $2.16 | $2.11 - $2.21 | +1.85% | Beat | +17.0% | 24 | 0 up, 0 down | Feb 8, 2024 | $1.94B |
| Sep 30, 2023 | $1.65 | $1.60 | $1.56 - $1.64 | +3.13% | Beat | +4.4% | 25 | 0 up, 0 down | Nov 7, 2023 | $1.75B |
| Jun 30, 2023 | $1.82 | $1.81 | $1.76 - $1.91 | +0.55% | Beat | 0.0% | 23 | 1 up, 0 down | Aug 1, 2023 | $1.87B |
| Mar 31, 2023 | $1.89 | $1.64 | $1.45 - $1.70 | +15.24% | Beat | +17.4% | 25 | 1 up, 0 down | May 2, 2023 | $1.83B |
| Dec 31, 2022 | $1.88 | $1.83 | $1.76 - $1.90 | +2.73% | Beat | -3.6% | 24 | 2 up, 0 down | Feb 3, 2023 | $1.83B |
| Sep 30, 2022 | $1.58 | $1.56 | $1.46 - $1.60 | +1.28% | Beat | -12.7% | 25 | 1 up, 1 down | Nov 2, 2022 | $1.67B |
| Jun 30, 2022 | $1.82 | $1.64 | $1.58 - $1.75 | +10.98% | Beat | -4.2% | 23 | 0 up, 1 down | Aug 2, 2022 | $1.78B |
| Mar 31, 2022 | $1.61 | $1.42 | $1.30 - $1.55 | +13.38% | Beat | -5.8% | 23 | 4 up, 0 down | May 3, 2022 | $1.66B |
| Dec 31, 2021 | $1.95 | $1.98 | $1.90 - $2.08 | -1.52% | Miss | -7.6% | 27 | 1 up, 1 down | Feb 7, 2022 | $1.78B |
| Sep 30, 2021 | $1.81 | $1.76 | $1.65 - $1.87 | +2.84% | Beat | 0.0% | 26 | N/A | Nov 4, 2021 | $1.69B |
| Jun 30, 2021 | $1.90 | $1.86 | $1.81 - $2.02 | +2.15% | Beat | +3700.0% | 26 | N/A | Aug 3, 2021 | $1.76B |
| Mar 31, 2021 | $1.71 | $1.53 | $1.26 - $1.77 | +11.76% | Beat | +0.6% | 27 | N/A | May 4, 2021 | $1.60B |
| Dec 31, 2020 | $2.11 | $2.06 | $1.76 - $2.38 | +2.43% | Beat | -8.3% | 27 | N/A | Feb 5, 2021 | $1.19B |
| Sep 30, 2020 | $1.81 | $1.08 | $0.72 - $1.43 | +67.59% | Beat | +2.3% | 27 | N/A | Nov 6, 2020 | $1.93B |
| Jun 30, 2020 | $0.05 | -$0.63 | -$1.32 - -$0.26 | +107.94% | Beat | -97.4% | 25 | N/A | Aug 4, 2020 | $1.23B |
| Mar 31, 2020 | $1.70 | $1.47 | $0.05 - $1.89 | +15.65% | Beat | -9.1% | 18 | N/A | May 11, 2020 | $1.78B |
| Dec 31, 2019 | $2.30 | $2.27 | $2.24 - $2.30 | +1.32% | Beat | +5.5% | 26 | N/A | Feb 4, 2020 | $2.13B |
| Sep 30, 2019 | $1.77 | $1.75 | $1.70 - $1.81 | +1.14% | Beat | +8.6% | 26 | N/A | Nov 5, 2019 | $1.89B |
| Jun 30, 2019 | $1.93 | $1.91 | $1.85 - $1.94 | +1.05% | Beat | +0.5% | 28 | N/A | Jul 26, 2019 | $1.99B |
| Mar 31, 2019 | $1.87 | $1.86 | $1.81 - $1.94 | +0.54% | Beat | -2.1% | 29 | N/A | Apr 26, 2019 | $1.98B |
| Dec 31, 2018 | $2.18 | $2.17 | $2.12 - $2.21 | +0.46% | Beat | +3.8% | 30 | N/A | Feb 1, 2019 | $2.07B |
| Sep 30, 2018 | $1.63 | $1.60 | $1.56 - $1.69 | +1.88% | Beat | -5.2% | 27 | N/A | Oct 26, 2018 | $1.84B |
| Jun 30, 2018 | $1.92 | $1.89 | $1.80 - $1.93 | +1.59% | Beat | -7.7% | 24 | N/A | Jul 27, 2018 | $2.01B |
| Mar 31, 2018 | $1.91 | $1.89 | $1.83 - $2.13 | +1.06% | Beat | -10.3% | 26 | N/A | Apr 26, 2018 | $2.02B |
| Dec 31, 2017 | $2.10 | $2.10 | $2.05 - $2.13 | 0.00% | In line | -1.9% | 25 | N/A | Jan 30, 2018 | $2.23B |
| Sep 30, 2017 | $1.72 | $1.74 | $1.57 - $2.13 | -1.15% | Miss | -3.9% | 26 | N/A | Nov 1, 2017 | $1.76B |
| Jun 30, 2017 | $2.08 | $2.10 | $2.07 - $2.13 | -0.95% | Miss | +3.0% | 26 | N/A | Jul 27, 2017 | $1.95B |
| Mar 31, 2017 | $2.13 | $2.11 | N/A | +0.95% | Beat | +6.5% | N/A | N/A | Apr 27, 2017 | $1.86B |
| Dec 31, 2016 | $2.14 | $2.11 | N/A | +1.42% | Beat | +2.4% | N/A | N/A | Jan 31, 2017 | $1.94B |
Annual EPS
EPS for the fiscal year ended Dec 31, 2025 was $8.20, up 2.5% from the year before. It was $7.95 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.
| Fiscal year ended | EPS | Change |
|---|---|---|
| Dec 31, 2025 | $8.20 | +2.5% |
| Dec 31, 2024 | $8.00 | +5.8% |
| Dec 31, 2023 | $7.56 | +9.7% |
| Dec 31, 2022 | $6.89 | -6.5% |
| Dec 31, 2021 | $7.37 | +30.0% |
| Dec 31, 2020 | $5.67 | -28.0% |
| Dec 31, 2019 | $7.87 | +3.0% |
| Dec 31, 2018 | $7.64 | -4.9% |
| Dec 31, 2017 | $8.03 | +1.0% |
| Dec 31, 2016 | $7.95 | N/A |
Earnings Calls
The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 8,900 words across 17 speakers.
| Call | Period ending | Words | Speakers | Transcript |
|---|---|---|---|---|
| 2026Q3 | Sep 30, 2026 | 8,894 | 17 | |
| 2026Q2 | Jun 30, 2026 | 8,328 | 16 | |
| 2026Q1 | Mar 31, 2026 | 5,939 | 19 | |
| 2025Q4 | Dec 31, 2025 | 9,069 | 18 | |
| 2025Q3 | Sep 30, 2025 | 8,273 | 17 | |
| 2025Q2 | Jun 30, 2025 | 8,465 | 18 | |
| 2025Q1 | Mar 31, 2025 | 9,248 | 19 | |
| 2024Q4 | Dec 31, 2024 | 9,343 | 16 |
2026Q3 Earnings Call
Opening remarks
David DeMartino Senior Vice President, Investor Relations Thank you, operator, and good morning, everyone. Welcome to Zimmer Biomet's Third Quarter 2026 Earnings Conference Call. Joining me on today's call are Ivan Tornos, our Chairman, President and CEO; and Paul Stellato, our Interim CFO and VP, Controller and Chief Accounting Officer. Before we get started, I'd like to remind you that our comments during this call will include forward-looking statements. Actual results may differ materially from those indicated by the forward-looking statements due to a variety of risks and uncertainties. For a detailed discussion of all these risks and uncertainties, in addition to the inherent limitations of such forward-looking statements, please refer to our SEC filings. Please note, we assume no obligation to update these forward-looking statements even if actual results or future expectations change materially. Additionally, the discussions on this call will include certain non-GAAP financial measures, some of which are forward-looking non-GAAP financial measures. Reconciliation of these measures to the most directly comparable GAAP financial measures and an explanation of our basis for calculating these measures are included within our third quarter earnings release, which can be found on our website, zimmerbiomet.com. With that, I'll turn the call over to Ivan. Ivan?
Ivan Tornos Chairman, President and CEO Thank you, David. Good morning, everyone, and thank you for joining today's call. I would like to start, as I always do, by thanking the more than 17,000 global Zimmer Biomet team members for your commitment, your resilience and, most importantly, your dedication to serving our customers and their patients each and every day. I'm grateful to work alongside you, and I'm proud of the noble work we do to alleviate pain and improve the quality of life for people around the world. Roughly six months from now, we will be celebrating our 100-year anniversary as a company. And as I often tell all of you, we are just getting started. Our boldest chapter remains ahead. During my prepared remarks this morning, I'll cover three things. First, I'll review our third quarter performance. Second, I'll discuss our increased outlook for 2026. And third, I'll provide an update on our three strategic priorities, which remain the same: people and culture, operational excellence, and innovation and diversification. To begin, we delivered total net sales of $2.63 billion, resulting in 3.1% reported growth and 3.7% constant currency growth in the quarter compared to the third quarter of 2025. Excluding the negative impact of our China distributor network consolidation strategy, a one-time headwind in fiscal year 2026, our constant currency growth in the quarter would have been 4.7%.
Frequently Asked Questions About ZBH
When is Zimmer Biomet Holdings's next earnings date?
Zimmer Biomet Holdings's next earnings report is expected for Feb 8, 2027.
Did ZBH beat earnings estimates last quarter?
Yes. Zimmer Biomet Holdings reported EPS of $1.90 for the quarter ended Sep 30, 2026, above the $1.89 estimate, a 0.53% surprise.
What EPS do analysts expect from ZBH next quarter?
The consensus EPS estimate for Zimmer Biomet Holdings for the quarter ending Dec 31, 2026 is $2.51 from 26 analysts, with estimates from $2.39 to $2.67.
How often does ZBH beat earnings estimates?
Zimmer Biomet Holdings beat the EPS estimate in each of the last 8 quarters, with an average surprise of +3.18%.
ZBH pages: Overview, Dividends, Earnings, Forecast, Financials, Valuation, Competitors, Government Contracts